<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We designed a phase II, open-label study to evaluate the efficacy, tolerability, safety, and pharmacokinetics of orally <z:chebi fb="1" ids="50845">doxycycline</z:chebi> (100 mg BID) and tauroursodeoxycholic acid (TUDCA) (250 mg three times/day) administered continuously for 12 months </plain></SENT>
<SENT sid="1" pm="."><plain>Primary endpoint is response rate defined as nonprogression of the <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> and of the <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Since July 2010, we enrolled 20 patients </plain></SENT>
<SENT sid="3" pm="."><plain>Seventeen patients have hereditary ATTR, two patients have senile systemic <z:hpo ids='HP_0011034'>amyloidosis</z:hpo>, and one is a domino recipient </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients completed 12-month treatment, 10 completed 6-month treatment, two discontinued because of poor tolerability, and one is lost at follow-up </plain></SENT>
<SENT sid="5" pm="."><plain>No serious adverse events were registered </plain></SENT>
<SENT sid="6" pm="."><plain>No clinical progression of cardiac involvement was observed </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> (<z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> Impairment Score in the Lower Limbs [<z:chebi fb="15" ids="53204">NIS</z:chebi>-LL] and Kumamoto score) remained substantially stable over 1 year </plain></SENT>
<SENT sid="8" pm="."><plain>These preliminary data indicate that the combination of Doxy-TUDCA stabilizes the disease for at least 1 year in the majority of patients with an acceptable toxicity profile </plain></SENT>
</text></document>